Reassessing blood product irradiation in haploidentical transplantation: a single-center perspective.

Autor:	Martínez-Hernández JP; Hematology Service, Hospital Universitario, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico., López-Mora YA; Hematology Service, Hospital Universitario, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico., Salazar-Riojas R; Hematology Service, Hospital Universitario, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico., Alvarado Navarro DM; Hematology Service, Hospital Universitario, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico., Hernández-Navarro AK; Hematology Service, Hospital Universitario, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico., Chavez-Estrada YO; Hematology Service, Hospital Universitario, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico., Gómez-De León A; Hematology Service, Hospital Universitario, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico., Gutierrez-Aguirre CH; Hematology Service, Hospital Universitario, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico., Colunga-Pedraza PR; Hematology Service, Hospital Universitario, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico., Cantú-Rodríguez OG; Hematology Service, Hospital Universitario, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico., Jaime-Pérez JC; Hematology Service, Hospital Universitario, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico., Gomez-Almaguer D; Hematology Service, Hospital Universitario, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico.
Jazyk:	angličtina
Zdroj:	Hematology (Amsterdam, Netherlands) [Hematology] 2024 Dec; Vol. 29 (1), pp. 2420144. Date of Electronic Publication: 2024 Oct 28.
DOI:	10.1080/16078454.2024.2420144
Abstrakt:	Objectives: The main objective was to investigate the incidence of transfusion-associated graft-versus-host disease (TA-GVHD) in patients who underwent haploidentical hematopoietic cell transplants (HCT) and received non-irradiated leukoreduced blood components. The secondary objective was to describe our leukodepletion results in blood products obtained by the filters employed at our center. Study Design and Methods: Clinical records from 2018 to 2023 were retrospectively analyzed, along with a prospective evaluation of residual leukocytes in blood components from June to November 2023 in order to confirm effectivity of our leukodepletion method. Results: 150 patients were included, no cases of TA-GVHD were reported after using non-irradiated blood products. The incidence of grade 3-4 acute and moderate-severe chronic GVHD was 12.7% (n = 19) and 2.7% (n = 4), respectively. The cumulative incidence of death was 39.3% (n = 52) with a 3.7-year overall survival (CI 95%, 3.3- 4.1 years). Leukodepletion analysis showed a reduction of 99.93% in platelet concentrates and 99.98% in packed red blood cells. Discussion: TA-GVHD in HCT remains a concern traditionally mitigated using blood product irradiation. Recent evidence obtained in favor of leukoreduction techniques question this need, especially in resource-limited settings. Conclusion: These findings support leukoreduction as a primary TA-GVHD preventive measure,along with the advantage in cost reduction.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu